Biotest Pharma signs supply, license pact with ADMA Biologics
Biotest Pharmaceuticals Corp has entered into a strategic long-term manufacturing, supply and license agreement with ADMA Biologics, Inc.
As per the terms of the deal, ADMA has agreed to buy exclusively from BPC its worldwide requirements of RSV immune globulin manufactured from human plasma containing RSV bodies.
The initial terms of the deal is for 10 years. BPC will get payment for manufacturing services provided under the deal as well as a percentage royalty on ADMA’s product revenues up to a specific maximum.
BPC has also agreed to provide manufacturing services and granted ADMA a license to use BPC’s proprietary fractionation and purification manufacturing process for intravenous immune globulin.
Jordan Siegel, Chief Executive Officer of BPC, “We are very pleased to partner with ADMA on their lead product candidate. Our ability to provide specialized contract manufacturing services will enable us to diversify our future revenue sources.”
Biotest Pharmaceuticals Corporation is a wholly owned subsidiary of Biotest AG. It researches, develops and manufactures biotherapeutic product with specialization in immunology and hematology.
Biotest AG is a provider of pharmaceutical and biotherapeutic drugs. Its value added chain extends from pre-clinical and clinical development to world-wide sales. The company has specialized mainly in areas of application of clinical immunology, hematology and intensive medicine.
Featured Articles
NTT and medical technology company Olympus put on a demonstration, showing the IOWN APN's low-latency capability, for the first cloud endoscopy system
Richter BioLogics GmbH & Co KG's a new biopharmaceutical GMP facility in Germany will boost production capabilities and local employment
A pilot study from GE Healthcare has shown the value of Portrait Mobile Continuous Monitoring Solution, a leap in post-surgical monitoring efficiency